Emanuele Nicastri
A5047826305- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- HIV Research and Treatment
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions
- Long-Term Effects of COVID-19
- Mosquito-borne diseases and control
- Viral Infections and Vectors
- Viral Infections and Outbreaks Research
- Poxvirus research and outbreaks
- Herpesvirus Infections and Treatments
- Bacillus and Francisella bacterial research
- Malaria Research and Control
- Cytomegalovirus and herpesvirus research
- Viral-associated cancers and disorders
- Disaster Response and Management
- SARS-CoV-2 detection and testing
- Hepatitis C virus research
- Parvovirus B19 Infection Studies
- COVID-19 epidemiological studies
- Respiratory viral infections research
- Hepatitis B Virus Studies
- COVID-19 and healthcare impacts
- Parasites and Host Interactions
- HIV-related health complications and treatments
Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani
2016-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2016-2025
Center for Prevention and Treatment of Infections
2001-2023
University of Siena
2018-2022
Ospedale Sacro Cuore Don Calabria
2022
General Hospital of Athens G. Genimatas
2022
Thriasio General Hospital of Elefsina
2022
National and Kapodistrian University of Athens
2022
Papageorgiou General Hospital
2022
General Hospital Asklepieio Voulas
2022
Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases, has shown in vitro activity against SARS-CoV-2. We provided remdesivir on compassionate-use basis to patients hospitalized with Covid-19, the illness caused by infection Patients were those confirmed SARS-CoV-2 who had an oxygen saturation of 94% or less while they breathing ambient air receiving support. received 10-day course remdesivir, consisting 200 mg administered intravenously day 1, followed 100 daily for...
In the WHO European Region, COVID-19 surveillance was implemented 27 January 2020. We detail first cases. As at 21 February, nine countries reported 47 Among 38 cases studied, were linked to two clusters in Germany and France, 14 infected China. Median case age 42 years; 25 male. Late detection of clusters’ index delayed isolation further local 5 March, there 4,250
Since May 2022, an outbreak of monkeypox has been ongoing in non-endemic countries. We report four cases Italy young adult men reporting condomless sexual intercourse. The patients are good clinical condition with no need for specific antiviral drugs. Biological samples from seminal fluid were positive viral DNA. For many other viruses found semen there is evidence transmission. possibility transmission virus needs to be investigated.
Abstract Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is indicative increased risk progression coronavirus disease 2019 (COVID-19) to respiratory failure. The SAVE-MORE double-blind, randomized controlled trial evaluated the efficacy and safety anakinra, an IL-1α/β inhibitor, in 594 patients with COVID-19 at progressing failure as identified by plasma suPAR ≥6 ng ml −1 , 85.9% ( n = 510) whom were receiving dexamethasone. At day 28, adjusted...
A man in his early 30s reported January 2016 a history of fever, asthenia and erythematous rash during stay Haiti. On return to Italy, ZIKV RNA was detected urine saliva 91 days after symptom onset, semen on day 188, six months onset. Our findings support the possibility sexual transmission highlight importance continuing investigate non-vector-borne infection.
SARS-CoV-2 is associated with a 3.4% mortality rate in patients severe disease. The pathogenesis of cases remains unknown. We performed an in-depth prospective analysis immune and inflammation markers two COVID-19 disease from presentation to convalescence. Peripheral blood 18 SARS-CoV-2-infected patients, 9 mild disease, was obtained at admission analyzed for T-cell activation profile, myeloid-derived suppressor cells (MDSCs) cytokine profiles. MDSC functionality tested vitro. In four...
Background The outbreak of coronavirus disease 2019 (COVID-19) has globally strained medical resources and caused significant mortality. Objective To develop validate a machine-learning model based on clinical features for severity risk assessment triage COVID-19 patients at hospital admission. Method 725 were used to train the model. This included retrospective cohort from Wuhan, China 299 hospitalised 23 December 13 February 2020, five cohorts with 426 eight centres in China, Italy Belgium...
Abstract Background Descriptions of the pathological features coronavirus disease-2019 (COVID-19) caused by novel zoonotic pathogen severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emanate from tissue biopsies, case reports, and small postmortem studies restricted to lung specific organs. Whole-body autopsy COVID-19 patients have been sparse. Methods To further define pathology SARS-CoV-2 across all body organs, we performed autopsies on 22 with (18 comorbidities 4 without...
IntroductionSeveral recent case reports have described common early chest imaging findings of lung pathology caused by 2019 novel Coronavirus (SARS-COV2) which appear to be similar those seen previously in SARS-CoV and MERS-CoV infected patients.ObjectiveWe present some remarkable the first two patients identified Italy with COVID-19 infection travelling from Wuhan, China. The follow-up X-Rays CT scans was also included, showing a progressive adult respiratory distress syndrome...
SARS-CoV-2 is a novel coronavirus, not encountered before by humans. The wide spectrum of clinical expression illness suggests that individual immune responses to play crucial role in determining the course after first infection. Immunological studies have focused on patients with moderate severe disease, demonstrating excessive inflammation tissues and organ damage. In order understand basis protective response COVID-19, we performed longitudinal follow-up, flow-cytometric serological...
On January 9 2020, the World Health Organization (WHO) declared identification, by Chinese authorities, of a novel coronavirus, further classified as SARS-CoV-2 responsible disease (COVID-19) ranging from asymptomatic cases to severe respiratory involvement. March WHO COVID-19 global pandemic. Italy is second most affected country infection after China. The "L. Spallanzani" National Institute for Infectious Diseases, IRCCS, Rome, Italy, has been first Italian hospital admit and manage...
A novel coronavirus (SARS-CoV-2) has been identified as the causative pathogen of an ongoing outbreak respiratory disease, now named COVID-19. Most cases and sustained transmission occurred in China, but travel-associated have reported other countries, including Europe Italy. Since symptoms are similar to infections, differential diagnosis travellers arriving from countries with wide-spread COVID-19 must include more common infections such influenza tract diseases.
<h2>Summary</h2><h3>Background</h3> Bacterial brain abscesses remain a serious central nervous system problem despite advances in neurosurgical, neuroimaging, and microbiological techniques the availability of new antibiotics. The successful treatment requires surgery, appropriate antibiotic therapy, eradication primary source; nevertheless many controversial issues on management this infection unresolved. <h3>Controversial issues</h3> aim GISIG (Gruppo Italiano di Studio sulle Infezioni...